CASI Pharmaceuticals, Inc. (CASI)

CASI Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	13.47	17.08	47.11	38.7	57.06
Short-Term Investments	2.62	13.69	4.23	9.87	9.31
Cash & Short-Term Investments	16.09	30.77	51.34	48.57	66.37
Cash Growth	-47.70%	-40.06%	5.69%	-26.82%	22.36%
Accounts Receivable	15.35	9.55	12.97	9.8	4.65
Other Receivables	-	0.59	-	-	-
Receivables	15.35	10.14	12.97	9.8	4.65
Inventory	5.25	15.88	6.14	1.91	1.36
Prepaid Expenses	2.89	2.56	2.98	1.69	1.65
Total Current Assets	39.58	59.34	73.42	61.97	74.03
Property, Plant & Equipment	11.36	11.63	13.23	21.82	10.76
Long-Term Investments	1.91	1.69	7.46	40.13	29.44
Other Intangible Assets	0.24	1.84	1.06	12.2	13.21
Other Long-Term Assets	0.59	0.77	1.06	2.18	0.3
Total Assets	53.67	75.27	96.23	138.3	127.73
Accounts Payable	2.72	4.44	3.29	2.22	3.26
Accrued Expenses	8.47	7.15	7.64	6.04	1.97
Short-Term Debt	-	-	-	-	1.29
Current Portion of Long-Term Debt	18.39	-	-	-	-
Current Portion of Leases	1.22	0.73	0.87	1.06	0.94
Current Income Taxes Payable	-	-	1.9	-	-
Current Unearned Revenue	2.47	2.54	2.62	0.06	-
Other Current Liabilities	3.18	1.87	0.69	3.81	0.52
Total Current Liabilities	36.45	16.73	17.01	13.19	7.98
Long-Term Debt	-	18.9	-	-	-
Long-Term Leases	2.54	1.62	0.48	1.11	0.97
Long-Term Unearned Revenue	-	-	-	2.83	2.35
Other Long-Term Liabilities	12.84	13.87	11.82	13.22	12.87
Total Liabilities	51.82	51.1	29.3	30.34	24.16
Common Stock	0	0	0	0	1.24
Additional Paid-In Capital	713.3	695.79	691.77	696.22	658.25
Retained Earnings	-700.08	-660.82	-637.16	-605.64	-570.5
Treasury Stock	-9.6	-9.6	-9.33	-8.03	-8.03
Comprehensive Income & Other	-1.77	-1.2	-0.7	1.95	0.59
Total Common Equity	1.85	24.17	44.57	84.5	81.54
Minority Interest	-	-	22.36	23.46	22.03
Shareholders' Equity	1.85	24.17	66.93	107.96	103.57
Total Liabilities & Equity	53.67	75.27	96.23	138.3	127.73
Total Debt	22.14	21.24	1.34	2.17	3.2
Net Cash (Debt)	-6.05	9.53	49.99	46.41	63.18
Net Cash Growth	-	-80.94%	7.73%	-26.55%	21.39%
Net Cash Per Share	-0.39	0.71	3.66	3.41	5.72
Filing Date Shares Outstanding	15.49	12.99	13.32	13.66	13.98
Total Common Shares Outstanding	15.49	13.38	13.46	13.98	12.39
Working Capital	3.12	42.62	56.42	48.78	66.05
Book Value Per Share	0.12	1.81	3.31	6.04	6.58
Tangible Book Value	1.61	22.33	43.51	72.3	68.33
Tangible Book Value Per Share	0.10	1.67	3.23	5.17	5.51
Machinery	6.58	6.68	1.24	1.73	1.62
Construction In Progress	-	0.02	5.73	12.1	1.19
Leasehold Improvements	7	7.19	7.16	1.13	0.99

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q